The Hippo

HOME| ADVERTISING | CONTACT US|

Valcyte for Cytomegalovirus in Children Concord NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Dr. Christian Hallowell
(603) 226-4960
253 Pleasant St
Concord, NH
Specialty
Pediatrics

Dr.Christian Hallowell
(603) 226-6100
253 Pleasant Street
Concord, NH
Gender
M
Education
Medical School: Dartmouth Med
Year of Graduation: 1973
Speciality
Pediatrician
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 2, reviews.

Data Provided by:
Imgrund Stephen P PHYS
(603) 224-9661
248 Pleasant Street
Concord, NH
 
Dr. Stephanie Cullop Lynch
(603) 226-4960
Pleasant St Memorial Bldg
Concord, NH
Specialty
Pediatrics

Mattlage Linda Arnp
(603) 224-1929
248 Pleasant Street
Concord, NH
 
Dr. George Anthony De Vito Jr
(603) 226-6100
253 Pleasant St
Concord, NH
Specialty
Pediatrics

Roger H Wicksman
(603) 224-1929
248 Pleasant St
Concord, NH
Specialty
Pediatrics

Data Provided by:
Dartmouth-Hitchcock-Concord - Family Practice
(603) 226-6108
253 Pleasant Street
Concord, NH
 
Renveyle Tad T MD
(603) 228-1521
2 1/2 Beacon Street
Concord, NH
 
Nephrology Associates
(603) 224-9995
248 Pleasant Street Suite G300
Concord, NH
 
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu